Polycystic Kidney Disease Drugs Market by Type and Geography - Forecast and Analysis 2021-2025

  • Published: Feb 2021
  • Pages: 120
  • SKU: IRTNTR70229

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The polycystic kidney disease drugs market size has the potential to grow by USD 485.71 million during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 6.90%. 

This report provides a detailed analysis of the market by type (ADPKD and ARPKD), geography (North America, Europe, Asia, and ROW), and key vendors. 

Market Overview

Polycystic-Kidney-Disease-Drugs-Market-Market-Size-2020-2025

Browse TOC and LoE with selected illustrations and example pages of Polycystic Kidney Disease Drugs Market

 Request a FREE sample now!

Market Competitive Analysis

The report analyzes the market’s competitive landscape and offers information on several market vendors, including: 

 

  • CorePharma LLC
  • Galapagos NV
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc.
  • Merck & Co. Inc.
  • Otsuka Holdings Co. Ltd.
  • Palladio Biosciences Inc.
  • Reata Pharmaceuticals Inc.
  • Sanofi

 

The polycystic kidney disease drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. Click here to uncover other successful business strategies deployed by the vendors. 

The market players also significantly leverage external market drivers such as high prevalence of chronic kidney diseases to achieve growth opportunities. However, factors such as lack of approved drugs will challenge the growth of the market participants. To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Download a free sample of the polycystic kidney disease drugs market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

This polycystic kidney disease drugs market analysis report also provides detailed information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities. 

Polycystic Kidney Disease Drugs Market: Key Drivers and Trends

  • The prevalence of special regulatory designations is one of the key drivers supporting the growth of the global polycystic kidney disease drugs market. 
  • The orphan products grants program (OPGP) funds the clinical research tests to check the efficacy and safety of drugs. 
  • Organizations such as the US FDA and EMA provide companies with market exclusivity for drugs that they manufacture for a certain period. 
  • These drug manufacturers also enjoy benefits such as tax credits for clinical trials and protocol assistance. 
  • Certain curative drugs also get awarded the fast track and orphan drug designations. 
  • During the market exclusivity period, the entry of generics is barred into the market, protecting the market sales of orphan drugs. 
  • The rising availability of favorable reimbursement policies is one of the key trends that will contribute to the growth of the global polycystic kidney disease drugs market.
  • Off-label drugs are mainly administered to individuals suffering from polycystic kidney disease. 
  • Government and non-government organizations have started introducing reimbursement policies to help patients in availing the required treatment for various kidney diseases. 
  • These policies are encouraging vendors to make further investments in R&D to release improved curative drugs.
  • As a result of the above-mentioned factors, the polycystic kidney disease drugs market will record a CAGR of 6.90% during the forecast period.

 

Grab your Free Sample now to unlock further information on other key market drivers

Polycystic Kidney Disease Drugs Market: Segmentation by Geography

Polycystic-Kidney-Disease-Drugs-Market-Market-Share-by-Region-2020-2025

For more insights on the market share of various regions Request for a FREE sample now!

50% of the market’s growth will originate from North America during the forecast period. The US is one of the key markets for polycystic kidney disease drugs in North America. Market growth in this region will be slower than the growth of the market in Asia.

The demand for drugs to treat PKD in the region is high because of the increasing incidence of the condition. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report. 

Polycystic Kidney Disease Drugs Market: Segmentation by Type

Polycystic-Kidney-Disease-Drugs-Market-Market-Share-by-Type-2020-2025

Request for a FREE sample and Get more information on the market contribution of various segments

ADPKD is the most common form of PKD and its prevalence is increasing across the world. Therefore, the drug development pipeline mostly contains therapeutic candidates for the treatment of ADPKD. Therefore, the growth of the market segment is expected to be significant during the forecast period.

Fetch actionable market insights on post COVID-19 impact on each segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the polycystic kidney disease drugs market size.

 

Event-Tickets-Market-Report

Request for a FREE sample

Polycystic Kidney Disease Drugs Market: Key Highlights of the Report for 2021-2025

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive polycystic kidney disease drugs market growth during the next five years
  • Precise estimation of the polycystic kidney disease drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the polycystic kidney disease drugs industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of polycystic kidney disease drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
The polycystic kidney disease drugs market growth will increase by $485.71 million during 2020-2025.
The polycystic kidney disease drugs market is expected to grow at a CAGR of 6.90% during 2020-2025.
Technavio has segmented the polycystic kidney disease drugs market by type (ADPKD and ARPKD) and geographic (North America, Europe, Asia, and ROW).
CorePharma LLC, Galapagos NV, Hikma Pharmaceuticals Plc, Johnson & Johnson, Kadmon Holdings Inc., Merck & Co. Inc., Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Reata Pharmaceuticals Inc., Sanofi are a few of the key vendors in the polycystic kidney disease drugs market.
North America will register the highest growth rate of 49.68% among the other regions. Therefore, the polycystic kidney disease drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
The key factors driving the polycystic kidney disease drugs market growth are:
  • High prevalence of chronic kidney diseases
  • Increasing research funding
The polycystic kidney disease drugs market vendors should focus on grabbing business opportunities from the adpkd segment as it accounted for the largest market share in the base year.
Safe and Secure SSL Encrypted

Single User:

2500 USD

Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase

Technavio's SUBSCRIPTION platform

Register for a free trial today and gain instant access to 17,000+ market research reports.

START YOUR FREE TRIAL

Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report

What other custmores say

17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>